[Adverse reactions of atazanavir, fosamprenavir and tipranavir in "real life"].
To precise adverse effects of atazanavir, fosamprenavir and tipranavir "in real life". Descriptive study of 3 protease inhibitor adverse effects stored in the French Bank of Pharmacovigilance. Nineteen adverse effects having at least possible links with antiretroviral drugs studied were reported. It was essentially hepatobiliary (atazanavir: 29/59, tipranavir: 4/6) and skin (fosamprenavir: 10/20) adverse reactions. These reactions, relatively "serious" (35.1%) led to the interruption of the person (or persons) medication (s) suspected (s) in 69 folds (82.1%) and evolved to healing without sequelae in 68 folds (81%). The drug side effects were for the most expected. However, their frequency and their seriously underline the interest of a post-AMM monitoring to reassess the drugs risk-benefit report.